According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758

Ertugliflozin / Metformin Formulation

| Version | Revision Date: | SDS Number: | Date of last issue: 06.04.2024 |
|---------|----------------|---------------|---------------------------------|
| 4.3 | 28.09.2024 | 9372630-00008 | Date of first issue: 27.08.2021 |

SECTION 1: Identification of the substance/mixture and of the company/undertaking

| 1.1 | Product identifier Trade name | : | Ertugliflozin / Metformin Formulation |
|-----|--|------|--|
| 1.2 | Relevant identified uses of th | ne s | ubstance or mixture and uses advised against |
| | Use of the Sub- stance/Mixture | : | Pharmaceutical |
| | Recommended restrictions on use | : | Not applicable |
| 1.3 | Details of the supplier of the | saf | ety data sheet |
| | Company | : | MSD 120 Moorgate EC2M 6UR London, United Kingdom |
| | Telephone | : | +44 (0) 2081548000 |
| | E-mail address of person responsible for the SDS | : | EHSDATASTEWARD@msd.com |

1.4 Emergency telephone number

1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008) as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567)

Acute toxicity, Category 4

H302: Harmful if swallowed.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008) as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567)

| Hazard pictograms | : | | • |
|-------------------|---|---------|-----------------------|
| Signal word | : | Warning | |
| Hazard statements | : | H302 | Harmful if swallowed. |

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758

:



Ertugliflozin / Metformin Formulation

| Version Revision Date: SDS Number: 4.3 28.09.2024 9372630-00008 | | Date of last issue: 06.04.2024 Date of first issue: 27.08.2021 |
|---|--|---|
| | | |

Precautionary statements

Prevention:

P264 Wash skin thoroughly after handling.P270 Do not eat, drink or smoke when using this product.

Response:

P301 + P312 + P330 IF SWALLOWED: Call a POISON CENTER/ doctor if you feel unwell. Rinse mouth.

Hazardous components which must be listed on the label: metformin hydrochloride

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

| Chemical name | CAS-No. EC-No. Index-No. Registration number | Classification | Concentration (% w/w) | |
|--|---|---|--------------------------|--|
| metformin hydrochloride | 1115-70-4 214-230-6 | Acute Tox. 4; H302 | >= 70 - < 90 | |
| Ertugliflozin | 1210344-83-4 | Acute Tox. 4; H302 Skin Corr. 1B; H314 Eye Dam. 1; H318 STOT RE 2; H373 (Kidney, Stomach, Prostate) | >= 0.1 - < 1 | |
| Substances with a workplace exposure limit : | | | | |
| Cellulose | 9004-34-6 232-674-9 | | >= 10 - < 20 | |

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice

: In the case of accident or if you feel unwell, seek medical advice immediately.



| Version 4.3 | Revision Date: 28.09.2024 | | DS Number: 72630-00008 | Date of last issue: 06.04.2024 Date of first issue: 27.08.2021 | | |
|----------------|---|-------|--|---|--|--|
| | | | When symptoms advice. | persist or in all cases of doubt seek medical | | |
| Pro | tection of first-aiders | : | and use the reco | First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8). | | |
| lf in | haled | : | If inhaled, remove Get medical atter | e to fresh air. ntion if symptoms occur. | | |
| In c | ase of skin contact | : | Wash with water Get medical atter | and soap. ntion if symptoms occur. | | |
| In c | ase of eye contact | : | - , | vell with water. htion if irritation develops and persists. | | |
| If swallowed | | : | If swallowed, DO NOT induce vomiting unless directed to do so by medical personnel. Get medical attention. Rinse mouth thoroughly with water. Never give anything by mouth to an unconscious person. | | | |
| 4.2 Mos | t important symptoms a | nd e | effects, both acute | e and delayed | | |
| Risl | <s< td=""><td>:</td><td>Harmful if swallow</td><td>wed.</td></s<> | : | Harmful if swallow | wed. | | |
| | | | the skin. | t can cause mechanical irritation or drying of the eyes can lead to mechanical irritation. | | |
| 4.3 Indic | ation of any immediate | me | dical attention and | d special treatment needed | | |
| Trea | atment | : | Treat symptomat | ically and supportively. | | |
| SECTIC | N 5: Firefighting mea | sur | es | | | |
| 5.1 Extir | nguishing media | | | | | |
| | able extinguishing media | : | Water spray Alcohol-resistant Carbon dioxide ((Dry chemical | | | |
| Uns med | uitable extinguishing dia | : | : None known. | | | |
| 5.2 Spec | cial hazards arising from | n the | e substance or mi | xture | | |
| - | cific hazards during fire- | : | Avoid generating concentrations, a potential dust exp | dust; fine dust dispersed in air in sufficient nd in the presence of an ignition source is a | | |

UK REACH Regulations SI 2019/758



Ertugliflozin / Metformin Formulation

| Vers 4.3 | sion Revision Date: 28.09.2024 | - | DS Number: 372630-00008 | Date of last issue: 06.04.2024 Date of first issue: 27.08.2021 |
|-------------------------------------|--|------|---|--|
| | Hazardous combustion pro ucts | d- : | Carbon oxides Nitrogen oxides (l Metal oxides | NOx) |
| 5.3 | Advice for firefighters | | | |
| | Special protective equipme for firefighters | nt : | | e, wear self-contained breathing apparatus. tective equipment. |
| Specific extinguishing meth- ods | | - : | cumstances and Use water spray f | measures that are appropriate to local cir- the surrounding environment. to cool unopened containers. ged containers from fire area if it is safe to do |

SECTION 6: Accidental release measures

| 6.1 Personal precautions, protecti | ve equipment and emergency procedures |
|------------------------------------|--|
| Personal precautions | Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8). |
| 6.2 Environmental precautions | |
| Environmental precautions | Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. If spillage enters rivers or watercourses, inform the Environment Agency (emergency telephone number 0800 807060). |
| 6.3 Methods and material for conta | ainment and cleaning up |
| Methods for cleaning up | Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items |

employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Ertugliflozin / Metformin Formulation

| Version | Revision Date: | SDS Number: | Date of last issue: 06.04.2024 |
|---------|----------------|---------------|---------------------------------|
| 4.3 | 28.09.2024 | 9372630-00008 | Date of first issue: 27.08.2021 |

SECTION 7: Handling and storage

7.1 Precautions for safe handling Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres. Local/Total ventilation Use only with adequate ventilation. : Do not breathe dust. Advice on safe handling : Do not swallow. Avoid contact with eves. Avoid prolonged or repeated contact with skin. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product. Take care to prevent spills, waste and minimize release to the environment. If exposure to chemical is likely during typical use, provide eye Hygiene measures flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

| Requirements for storage areas and containers | : | Keep in properly labelled containers. Store in accordance with the particular national regulations. |
|---|---|---|
| Advice on common storage | : | Do not store with the following product types: Strong oxidizing agents |
| 7.3 Specific end use(s) Specific use(s) | : | No data available |

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

| Occupational Exposure Limits | | | | |
|------------------------------|--|--|--|--|
| dust of any kind | 10 mg/m3 | | | |
| - | Value type (Form of exposure): TWA (Inhalable) | | | |

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Ertugliflozin / Metformin Formulation

| | Jumber:Date of last issue: 06.04.202430-00008Date of first issue: 27.08.2021 |
|--|--|
|--|--|

Basis: GB EH40

4 mg/m3

Value type (Form of exposure): TWA (Respirable fraction) Basis: GB EH40

| Components | CAS-No. | Value type (Form of exposure) | Control parameters | Basis |
|------------------------------|------------------|-------------------------------|----------------------------|----------|
| metformin hydro- chloride | 1115-70-4 | TWA | 1 mg/m3 (OEB 1) | Internal |
| Cellulose | 9004-34-6 | TWA (inhalable dust) | 10 mg/m3 | GB EH40 |
| | | TWA (Respirable dust) | 4 mg/m3 | GB EH40 |
| | | STEL (inhalable dust) | 20 mg/m3 | GB EH40 |
| Ertugliflozin | 1210344- 83-4 | TWA | 10 µg/m3 (OEB 3) | Internal |
| | | Wipe limit | 100 µg/100 cm ² | Internal |

8.2 Exposure controls

Engineering measures

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

Personal protective equipment

| Eye/face protection Hand protection | : | Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols. |
|---|---|---|
| Material | : | Chemical-resistant gloves |
| Remarks Skin and body protection Respiratory protection | : | Consider double gloving. Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing. If adequate local exhaust ventilation is not available or expo- |
| | | sure assessment demonstrates exposures outside the rec- ommended guidelines, use respiratory protection. Equipment should conform to BS EN 143 |

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Ertugliflozin / Metformin Formulation

| Version 4.3 | Revision Date: 28.09.2024 | SDS Number: 9372630-00008 | Date of last issue: 06.04.2024 Date of first issue: 27.08.2021 | |
|----------------|---------------------------|------------------------------|---|--|
| Fil | ter type | : Particulates type (P) | | |

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

| Appearance Colour Odour Odour Threshold | : | powder No data available No data available No data available |
|---|---|--|
| рН | : | No data available |
| Melting point/freezing point | : | No data available |
| Initial boiling point and boiling range | : | No data available |
| Flash point | : | Not applicable |
| Evaporation rate | : | Not applicable |
| Flammability (solid, gas) | : | May form explosive dust-air mixture during processing, han- dling or other means. |
| Upper explosion limit / Upper flammability limit | : | No data available |
| Lower explosion limit / Lower flammability limit | : | No data available |
| Vapour pressure | : | Not applicable |
| Relative vapour density | : | Not applicable |
| Relative density | : | No data available |
| Density | : | No data available |
| Solubility(ies) Water solubility Partition coefficient: n- octanol/water | : | No data available Not applicable |
| Auto-ignition temperature | : | No data available |
| Decomposition temperature | : | No data available |
| Viscosity Viscosity, kinematic | : | Not applicable |
| Explosive properties | : | Not explosive |
| Oxidizing properties | : | The substance or mixture is not classified as oxidizing. |

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Ertugliflozin / Metformin Formulation

| Version 4.3 | Revision Date: 28.09.2024 | SDS Number: 9372630-00008 | Date of last issue: 06.04.2024 Date of first issue: 27.08.2021 | | | | |
|----------------|--|------------------------------|---|--|--|--|--|
| | information mability (liquids) | : No data availa | ble | | | | |
| Particle size | | : No data availa | ble | | | | |
| SECTION | SECTION 10: Stability and reactivity | | | | | | |

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

| Hazardous reactions | : | May form explosive dust-air mixture during processing, han- dling or other means. Can react with strong oxidizing agents. |
|-----------------------------|---|---|
| 10.4 Conditions to avoid | | |
| Conditions to avoid | : | Heat, flames and sparks. Avoid dust formation. |
| 10.5 Incompatible materials | | |
| Materials to avoid | : | Oxidizing agents |

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on toxicological effects

| Information on likely routes of | : | Inhalation |
|---------------------------------|---|--------------|
| exposure | | Skin contact |
| | | Ingestion |

Acute toxicity

Harmful if swallowed.

Product:

Acute oral toxicity : Acute toxicity estimate: 1,337 mg/kg Method: Calculation method

Eve contact

Components:

metformin hydrochloride:

| Acute oral toxicity | : LD50 (Rat): 1,000 mg/kg |
|---------------------|---------------------------|
|---------------------|---------------------------|

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



| Versio 4.3 | on | Revision Date: 28.09.2024 | | OS Number: 72630-00008 | Date of last issue: 06.04.2024 Date of first issue: 27.08.2021 | | |
|---------------|-------------------|---|------|---|---|--|--|
| | | | | LD50 (Mouse): 1, | 450 - 3,500 mg/kg | | |
| | | | | LD50 (Monkey): 463 mg/kg | | | |
| | | | | LD50 (Rabbit): 350 mg/kg | | | |
| | | | | LD50 (Guinea pig | ı): 500 mg/kg | | |
| E | Ertugli | flozin: | | | | | |
| A | Acute o | oral toxicity | : | LD50 (Rat): 500 r | ng/kg | | |
| ŀ | Acute i | nhalation toxicity | : | Remarks: No data | a available | | |
| ŀ | Acute c | lermal toxicity | : | Remarks: No data | a available | | |
| C | Cellulo | se: | | | | | |
| ŀ | Acute o | oral toxicity | : | LD50 (Rat): > 5,0 | 00 mg/kg | | |
| Ļ | Acute i | nhalation toxicity | : | LC50 (Rat): > 5.8 Exposure time: 4 Test atmosphere: | h | | |
| A | Acute o | dermal toxicity | : | LD50 (Rabbit): > | 2,000 mg/kg | | |
| - | | orrosion/irritation ssified based on availa | able | information. | | | |
| <u>c</u> | Compo | onents: | | | | | |
| | | min hydrochloride: | | | | | |
| | Specie: Result | S | : | Rabbit Mild skin irritation | | | |
| E | Ertugli | flozin: | | | | | |
| F | Result | | : | Corrosive | | | |
| | | s eye damage/eye irr ssified based on availa | | | | | |
| <u>c</u> | Compo | onents: | | | | | |
| | | min hydrochloride: | | | | | |
| | Specie: Result | S | : | Rabbit Mild eye irritation | | | |
| E | Ertugli | flozin: | | | | | |
| F | Result | | : | Severe irritation | | | |

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



| Version 4.3 | Revision Date: 28.09.2024 | | S Number: 72630-00008 | Date of last issue: 06.04.2024 Date of first issue: 27.08.2021 |
|------------------------------|--|---------|---|---|
| Resp | iratory or skin sensi | tisatio | n | |
| - | sensitisation lassified based on ava | ailable | information. | |
| - | iratory sensitisation lassified based on ava | ailable | information. | |
| Com | ponents: | | | |
| Ertuç Test Resu | | : | Local lymph nod Not a skin sensit | |
| | n cell mutagenicity lassified based on ava | ailable | information. | |
| <u>Com</u> | ponents: | | | |
| metfo | ormin hydrochloride: | | | |
| Geno | otoxicity in vitro | : | Test Type: Bacte Result: negative | rial reverse mutation assay (AMES) |
| | | | Test Type: in vitr Test system: mo Result: negative | o assay use lymphoma cells |
| | | | | mosomal aberration man lymphocytes |
| Genc | otoxicity in vivo | : | Test Type: Micro Species: Mouse Application Route Result: negative | |
| Ertuc | gliflozin: | | | |
| - | toxicity in vitro | : | Test Type: Bacte Result: negative | erial reverse mutation assay (AMES) |
| | | | Test Type: Chror Result: negative | nosome aberration test in vitro |
| Genc | otoxicity in vivo | : | Test Type: Mami cytogenetic assa Species: Rat Result: negative | malian erythrocyte micronucleus test (in vivo y) |
| Cellu | llose: | | | |
| Geno | otoxicity in vitro | : | Test Type: Bacte Result: negative | erial reverse mutation assay (AMES) |



| Version 4.3 | Revision Date: 28.09.2024 | | DS Number: 72630-00008 | Date of last issue: 06.04.2024 Date of first issue: 27.08.2021 |
|----------------|-------------------------------------|--------|---|---|
| | | | Test Type: In vit Result: negative | ro mammalian cell gene mutation test |
| Geno | Genotoxicity in vivo | | Test Type: Mam cytogenetic assa Species: Mouse Application Rou Result: negative | te: Ingestion |
| | inogenicity | | | |
| | lassified based on avai ponents: | ilable | information. | |
| | | | | |
| | ormin hydrochloride: | | | |
| Spec | | | Mouse | |
| | sure time | | 91 weeks | |
| Dose | | ÷ | 1500 mg/kg bod | y weight |
| Resu | IL | • | negative | |
| Spec | ies | : | Rat, male | |
| | cation Route | : | Oral | |
| Expo | sure time | : | 104 weeks | |
| Dose | | : | 900 mg/kg body | weight |
| Resu | lt | : | negative | |
| Spec | ies | | Rat, female | |
| | cation Route | ÷ | Oral | |
| | sure time | : | 104 weeks | |
| LOAE | | : | 900 mg/kg body | weight |
| Resu | lt | : | negative | 0 |
| Targe | et Organs | : | Uterus (including | g cervix) |
| Rema | arks | : | The mechanism mans. | or mode of action may not be relevant in hu- |
| Ertuc | gliflozin: | | | |
| Spec | • | | Mouse | |
| | cation Route | • | Oral | |
| | sure time | ÷ | 2 Years | |
| Resu | | : | negative | |
| Spec | ioc | | Rat | |
| | cation Route | : | Oral | |
| | sure time | : | 2 Years | |
| Resu | | : | negative | |
| Carci ment | nogenicity - Assess- | : | Weight of evider cinogen | nce does not support classification as a car- |
| mont | | | Sinoyon | |
| Cellu | lose: | | | |
| Spec | ies | : | Rat | |
| -1.20 | | | | |

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



| Version 4.3 | Revision Date: 28.09.2024 | SDS Number: 9372630-00008 | Date of last issue: 06.04.2024 Date of first issue: 27.08.2021 |
|----------------|---|---|---|
| | cation Route sure time t | : Ingestion : 72 weeks : negative | |
| - | oductive toxicity assified based on avai | lable information. | |
| <u>Comp</u> | oonents: | | |
| metfo | ormin hydrochloride: | | |
| Effect | s on fertility | | t |
| Effect ment | s on foetal develop- | | t |
| | | Species: Ra Application I Embryo-foet | |
| Ertug | liflozin: | | |
| - | s on fertility | Species: Ra Application I Fertility: NO Remarks: M | |
| | | Species: Ra Application I Fertility: NO | |
| Effect ment | s on foetal develop- | Species: Ra Application I Developmer | |
| | | Species: Ra Application I | |

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Ertugliflozin / Metformin Formulation

| Vers 4.3 | sion | Revision Date: 28.09.2024 | | 0S Number: 72630-00008 | Date of last issue: 06.04.2024 Date of first issue: 27.08.2021 | | |
|-------------|--------------------------------------|---|------|---|---|--|--|
| | | | | Remarks: No sigr | ificant adverse effects were reported | | |
| | Cellulose: Effects on fertility : | | : | : Test Type: One-generation reproduction toxicity str Species: Rat Application Route: Ingestion Result: negative | | | |
| | Effects ment | on foetal develop- | : | Test Type: Fertilit Species: Rat Application Route Result: negative | y/early embryonic development : Ingestion | | |
| | | - single exposure ssified based on availa | able | information. | | | |
| | | repeated exposure ssified based on availa | able | information. | | | |
| | Compo | onents: | | | | | |
| | | ure routes Organs | : | Oral Kidney, Stomach, May cause damag exposure. | Prostate ge to organs through prolonged or repeated | | |
| | Repea | ted dose toxicity | | | | | |
| | Compo | onents: | | | | | |
| | metfor | min hydrochloride: | | | | | |
| | | - ation Route ure time | : : | Rat 125 mg/kg Oral 1 year No significant adv | erse effects were reported | | |
| | | - ation Route ure time | : | Rabbit 100 mg/kg Oral 1 Year No significant adv | erse effects were reported | | |
| | | - ation Route ure time | : | Dog 50 mg/kg Subcutaneous 2 year No significant adv | erse effects were reported | | |

Ertugliflozin:

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Ertugliflozin / Metformin Formulation

| Version 4.3 | Revision Date: 28.09.2024 | SDS Number: 9372630-00008 | Date of last issue: 06.04.2024 Date of first issue: 27.08.2021 |
|----------------|--|---|---|
| | | : Rat : 500 mg/kg : Oral : 30 d | |
| Expos | | : Rat : 250 mg/kg : Oral : 30 d : Kidney | |
| Expos | | : Rat : 25 mg/kg : Oral : 180 d : Kidney, Bone, S | Stomach |
| | | : Rat : 25 mg/kg : 90 d : Kidney, Gastroir | ntestinal tract, Prostate |
| | L ation Route ure time | : Dog : 150 mg/kg : Oral : 270 d : No significant ad | dverse effects were reported |
| | L ation Route ure time | : Mouse : 100 mg/kg : Oral : 90 d : No significant ad | dverse effects were reported |
| Expos | L ation Route ure time t Organs | : Mouse : 100 mg/kg : Oral : 28 d : Bone : No significant ad | dverse effects were reported |
| | es | : Rat : >= 9,000 mg/kg : Ingestion : 90 Days | |

Aspiration toxicity

Not classified based on available information.

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Ertugliflozin / Metformin Formulation

| | of last issue: 06.04.2024 of first issue: 27.08.2021 |
|--|---|
|--|---|

Experience with human exposure

Components:

| metformin hydrochloride: | | |
|--|---|---|
| Skin contact Eye contact Ingestion | : | Remarks: May irritate skin. Remarks: May irritate eyes. Symptoms: Diarrhoea, Nausea, Vomiting, Gastrointestinal |
| Ertugliflozin: Ingestion | : | discomfort, flatulence, asthenia, Fatigue, Headache Symptoms: The most common side effects are:, Headache, constipation, Diarrhoea, Nausea, urinary tract infection, mus- |
| | | cle pain, upper respiratory tract infection |

SECTION 12: Ecological information

12.1 Toxicity

| Components: | | |
|---|---|---|
| metformin hydrochloride: | | |
| Toxicity to algae/aquatic plants | : | EC50 (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 |
| | | NOEC (Pseudokirchneriella subcapitata (green algae)): 100 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 |
| Toxicity to microorganisms | : | EC50 : > 1,000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209 |
| Toxicity to fish (Chronic tox- icity) | : | NOEC: 10 mg/l Exposure time: 33 d Species: Pimephales promelas (fathead minnow) Method: OECD Test Guideline 210 |
| Toxicity to daphnia and other aquatic invertebrates (Chron- ic toxicity) | : | NOEC: 40 mg/l Exposure time: 21 d Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211 |
| Ertugliflozin: | | |
| Toxicity to algae/aquatic plants | : | EC50 (Pseudokirchneriella subcapitata (green algae)): 77 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 |

SAFETY DATA SHEET According to REACH Regulation (EC) No 1907

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



| Vers 4.3 | sion | Revision Date: 28.09.2024 | - | 0S Number: 72630-00008 | Date of last issue: 06.04.2024 Date of first issue: 27.08.2021 |
|-------------|---|------------------------------|-----|---|---|
| | Toxicity to microorganisms | | | NOEC (Pseudoki mg/l Exposure time: 72 Method: OECD T | |
| | | | : | EC50 : > 1,000 m Exposure time: 3 Test Type: Respin Method: OECD T | ĥ |
| | | | | NOEC : 1,000 mg Exposure time: 3 Test Type: Respir Method: OECD T | h |
| | Toxicity to fish (Chronic tox- icity) | | : | Method: OECD T | 2 d ales promelas (fathead minnow) est Guideline 210 city at the limit of solubility |
| | Toxicity to daphnia and other aquatic invertebrates (Chron- ic toxicity) | | : | Method: OECD T | 1 d i magna (Water flea) |
| | Cellulo | se: | | | |
| | Toxicity | v to fish | : | Exposure time: 48 | ipes (Japanese medaka)): > 100 mg/l 3 h on data from similar materials |
| 12.2 | Persist | tence and degradabil | ity | | |
| | Compo | onents: | | | |
| | metfor | min hydrochloride: | | | |
| | Biodegi | radability | : | Result: rapidly de Biodegradation: 4 Exposure time: 2 | 50 % |
| | Ertugli | flozin: | | | |
| | Biodegi | radability | : | Result: Not readil Biodegradation: Exposure time: 28 | 40.8 % |
| | Cellulo | se: | | | |
| | Biodegi | radability | : | Result: Readily bi | odegradable. |

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Ertugliflozin / Metformin Formulation

| Version 4.3 | Revision Date: 28.09.2024 | SDS Numb 9372630-00 | | |
|-----------------------------|--|------------------------|---|-----------|
| 12.3 Bioa | ccumulative potential | | | |
| <u>Com</u> | ponents: | | | |
| Partit | ormin hydrochloride: tion coefficient: n- nol/water | : log Pow | -2 | |
| Partit | gliflozin: tion coefficient: n- nol/water | : log Pow | 2.47 | |
| 12.4 Mob | ility in soil | | | |
| <u>Com</u> | ponents: | | | |
| Distri | ormin hydrochloride: bution among environ- al compartments | : log Koc: Method: | 1.3 DECD Test Guideline 106 | |
| Distri | gliflozin: bution among environ- al compartments | : log Koc | 2.88 | |
| 12.5 Resu | ults of PBT and vPvB a | ssessment | | |
| <u>Prod</u> Asse | <u>uct:</u> ssment | to be eit | tance/mixture contains no components of er persistent, bioaccumulative and toxic istent and very bioaccumulative (vPvB) a igher. | (PBT), or |
| 12.6 Othe | er adverse effects | | | |
| <u>Prod</u> Endo tial | uct: crine disrupting poten- | ered to | tance/mixture does not contain compone ave endocrine disrupting properties for e to UK REACH Article 57(f). | |
| SECTIO | N 13: Disposal consi | derations | | |

13.1 Waste treatment methods

| Product | | Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer. |
|------------------------|---|--|
| Contaminated packaging | : | Empty containers should be taken to an approved waste han- dling site for recycling or disposal. If not otherwise specified: Dispose of as unused product. |

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Ertugliflozin / Metformin Formulation

| Version | Revision Date: | SDS Number: | Date of last issue: 06.04.2024 |
|---------|----------------|---------------|---------------------------------|
| 4.3 | 28.09.2024 | 9372630-00008 | Date of first issue: 27.08.2021 |

SECTION 14: Transport information

14.1 UN number

| ADN | : Not regulated as a dangerous good |
|---------------------------|-------------------------------------|
| ADR | : Not regulated as a dangerous good |
| RID | : Not regulated as a dangerous good |
| IMDG | : Not regulated as a dangerous good |
| ΙΑΤΑ | : Not regulated as a dangerous good |
| 14.2 UN proper shipping | name |
| ADN | : Not regulated as a dangerous good |
| ADR | : Not regulated as a dangerous good |
| RID | : Not regulated as a dangerous good |
| IMDG | : Not regulated as a dangerous good |
| ΙΑΤΑ | : Not regulated as a dangerous good |
| 14.3 Transport hazard cla | iss(es) |
| ADN | : Not regulated as a dangerous good |
| ADR | : Not regulated as a dangerous good |
| RID | : Not regulated as a dangerous good |
| IMDG | : Not regulated as a dangerous good |
| ΙΑΤΑ | : Not regulated as a dangerous good |
| 14.4 Packing group | |
| ADN | : Not regulated as a dangerous good |
| ADR | : Not regulated as a dangerous good |
| RID | : Not regulated as a dangerous good |
| IMDG | : Not regulated as a dangerous good |
| IATA (Cargo) | : Not regulated as a dangerous good |
| IATA (Passenger) | : Not regulated as a dangerous good |
| 14.5 Environmental haza | rds |

Not regulated as a dangerous good

14.6 Special precautions for user

Not applicable

14.7 Transport in bulk according to Annex II of Marpol and the IBC CodeRemarks: Not applicable for product as supplied.



Ertugliflozin / Metformin Formulation

| Version | Revision Date: | SDS Number: | Date of last issue: 06.04.2024 |
|---------|----------------|---------------|---------------------------------|
| 4.3 | 28.09.2024 | 9372630-00008 | Date of first issue: 27.08.2021 |

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

Relevant EU provisions transposed through retained EU law

| UK REACH List of restrictions (Annex 17) | : | Not applicable |
|--|----|----------------|
| UK REACH Candidate list of substances of very high concern (SVHC) for Authorisation | : | Not applicable |
| The Persistent Organic Pollutants Regulations (retained Regulation (EU) 2019/1021 as amended for Great Brit- | : | Not applicable |
| ain) Regulation (EC) on substances that deplete the ozone laver | : | Not applicable |
| UK REACH List of substances subject to authorisation (Annex XIV) | : | Not applicable |
| GB Export and import of hazardous chemicals - Prior Informed Consent (PIC) Regulation | : | Not applicable |
| Control of Major Accident Hazards Regulations 2015 (CC Not applicable | MA | .H) |

The components of this product are reported in the following inventories:

| AICS | : | not determined |
|-------|---|----------------|
| DSL | : | not determined |
| IECSC | : | not determined |

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

| SECTION 16: Other information | | | | |
|-------------------------------|--|--|--|--|
| Other information | : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines. | | | |
| Full text of H-Statements | i | | | |
| H302 | : Harmful if swallowed. | | | |
| H314 | : Causes severe skin burns and eye damage. | | | |
| H318 | : Causes serious eye damage. | | | |
| H373 | : May cause damage to organs through prolonged or repeated exposure if swallowed. | | | |
| Full text of other abbrevi | ations | | | |
| Acute Tox. | : Acute toxicity | | | |
| Eye Dam. | : Serious eye damage | | | |
| Skin Corr. | : Skin corrosion | | | |
| STOT RE | : Specific target organ toxicity - repeated exposure | | | |

GB EH40 GB EH40

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Ertugliflozin / Metformin Formulation

| Version | Revision Date: 28.09.2024 | SDS Number: | Date of last issue: 06.04.2024 |
|---------|---------------------------|----------------|---------------------------------|
| 4.3 | | 9372630-00008 | Date of first issue: 27.08.2021 |
| GB EH40 | | : UK. EH40 WEL | - Workplace Exposure Limits |

| | • | UK. EH40 WEL - WORKPIACE EXPOSURE LIMITS |
|--------|---|--|
| / TWA | : | Long-term exposure limit (8-hour TWA reference period) |
| / STEL | : | Short-term exposure limit (15-minute reference period) |

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

| Sources of key data used to | : | Internal technical data, data from raw material SDSs, OECD |
|-----------------------------|---|--|
| compile the Safety Data | | eChem Portal search results and European Chemicals Agen- |
| Sheet | | cy, http://echa.europa.eu/ |

H302

Classification of the mixture:

Acute Tox. 4

Classification procedure:

Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text.



Ertugliflozin / Metformin Formulation

| Version | Revision Date: | SDS Number: | Date of last issue: 06.04.2024 |
|---------|----------------|---------------|---------------------------------|
| 4.3 | 28.09.2024 | 9372630-00008 | Date of first issue: 27.08.2021 |

Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

GB / EN